Viewing Study NCT02912234


Ignite Creation Date: 2025-12-25 @ 2:23 AM
Ignite Modification Date: 2026-01-07 @ 7:31 PM
Study NCT ID: NCT02912234
Status: COMPLETED
Last Update Posted: 2016-11-21
First Post: 2016-09-19
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
Sponsor: Bristol-Myers Squibb
Organization:

Study Overview

Official Title: Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
Status: COMPLETED
Status Verified Date: 2016-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study is to evaluate the effects of multiple-dose clarithromycin on the single-dose pharmacokinetics (PK) of apixaban with parameters like Cmax, AUC(INF), and AUC(0-T).
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: